Roche AG, a global leader in healthcare, is dedicated to preventing, stopping, and curing diseases through scientific excellence and innovation. Headquartered in Basel, Switzerland, the company operates with a mission to improve people’s quality of life and extend lifespans by delivering transformative medicines and diagnostic solutions.
Table of Contents
Company Profile
With over 100,000 employees worldwide, Roche combines its strengths in Pharmaceuticals and Diagnostics to address some of the most complex challenges in healthcare, focusing on oncology, cardiovascular-metabolic diseases, and neurological disorders. The company’s purpose, “Doing now what patients need next,” drives its commitment to scientific rigor, ethical practices, and equitable access to medical innovations. In 2024, Roche reported Group sales of CHF 60.5 billion, a 7% increase at constant exchange rates, reflecting strong demand for its innovative diagnostic tests and medicines.
Roche fosters a culture of innovation, sustainability, and collaboration, with state-of-the-art research facilities like the newly opened Roche Innovation Center Basel. This facility, equipped with cutting-edge labs, promotes interdisciplinary cooperation to advance medical science. The company’s sustainability strategy prioritizes access to healthcare, employee well-being, and environmental responsibility, aiming for net-zero emissions by 2045 and absolute zero by 2050. Roche’s global reach, strategic acquisitions, and partnerships with over 250 external entities ensure it remains at the forefront of healthcare innovation, delivering value to patients, healthcare systems, and stakeholders.
Business Segments
Roche operates through two core divisions: Pharmaceuticals and Diagnostics. These divisions work synergistically to address major disease areas, including oncology, neurology, and cardiovascular-metabolic diseases, which are projected to account for nearly 50% of the global disease burden by 2035. Below is a detailed overview of each segment, including their revenue contributions for 2024.
Pharmaceuticals Division
The Pharmaceuticals Division focuses on developing and delivering innovative medicines to treat serious and life-threatening conditions. Roche’s portfolio includes first-in-class and best-in-class therapies, with at least 80% of its pipeline molecules targeting these distinctions. Key therapeutic areas include oncology, neurology, hematology, and rare diseases. In 2024, the division launched transformative medicines such as Itovebi for breast cancer and expanded its portfolio through strategic acquisitions and partnerships targeting cancer, autoimmune diseases, eye diseases, and obesity.
Notable products include:
- Vabysmo: Treats severe eye diseases, a key growth driver in 2024.
- Phesgo: A breast cancer therapy contributing significantly to sales.
- Ocrevus: A leading treatment for multiple sclerosis.
- Hemlibra: A therapy for haemophilia A, improving patient outcomes.
- Itovebi: A new breast cancer medicine reducing the risk of death or disease progression by over 50%.
- PiaSky: A subcutaneous therapy for paroxysmal nocturnal haemoglobinuria (PNH), allowing home administration.
- Alecensa: Reduces relapse or death risk in early lung cancer by 76%.
- Gazyva/Gazyvaro: Shows promise for lupus nephritis based on phase III data.
The division leverages artificial intelligence (AI) to enhance drug development, making it more targeted and efficient. In 2024, Pharmaceuticals contributed significantly to the Group’s 7% sales growth, though specific revenue figures for the division alone are not isolated in the provided data.
Diagnostics Division
The Diagnostics Division is the world leader in in vitro diagnostics, offering solutions for prevention, screening, diagnosis, treatment, and monitoring. In 2024, the division launched 21 diagnostic tests, five diagnostic platforms, and seven digital solutions, including the Accu-Chek SmartGuide for diabetes management. Its immunodiagnostic tests were among the key growth drivers. The division’s focus on precision diagnostics, powered by AI, enables earlier detection and better disease management, aligning with Roche’s goal of reducing healthcare system burdens.
Revenue Breakup
In 2024, Roche reported Group sales of CHF 60.5 billion, with a 7% growth at constant exchange rates. The base business (excluding COVID-19-related products) grew by 9%. While the document does not provide a precise revenue split between Pharmaceuticals and Diagnostics, both divisions were key contributors to the overall growth. The following table estimates the revenue contribution based on the emphasis on both divisions as major drivers:
| Business Segment | Estimated Revenue Contribution (%) | Key Growth Drivers |
|---|---|---|
| Pharmaceuticals | ~60% | Vabysmo, Phesgo, Ocrevus, Hemlibra, Itovebi, PiaSky, Alecensa |
| Diagnostics | ~40% | Immunodiagnostic tests, Accu-Chek SmartGuide, mass spectrometry solutions |
Note: The revenue percentages are estimated based on the document’s emphasis on both divisions’ contributions to the 7% Group sales growth, with Pharmaceuticals likely contributing a larger share due to its broader portfolio and new medicine launches.
Company History
Founded in 1896, Roche has grown from a small Swiss enterprise into a global healthcare powerhouse over its 125-year history. Its journey is marked by a relentless pursuit of scientific excellence and innovation, transforming the lives of millions through groundbreaking medicines and diagnostics. Below is a comprehensive overview of Roche’s historical milestones:
- 1896: Fritz Hoffmann-La Roche establishes F. Hoffmann-La Roche Ltd in Basel, Switzerland, with a vision to produce high-quality, standardized medicines at a time when the pharmaceutical industry was nascent.
- Early 20th Century: Roche pioneers the production of vitamins, becoming a leader in nutritional science. This era establishes its reputation for innovation and quality.
- Mid-20th Century: The company expands into diagnostics, laying the foundation for its dual expertise in pharmaceuticals and diagnostics. Roche introduces significant therapies, including antidepressants and antibiotics, addressing critical health needs.
- Late 20th Century: Roche becomes a global leader in oncology, launching transformative cancer therapies. Its acquisition of Genentech in 1990 marks a pivotal moment, enhancing its biotechnology capabilities and strengthening its U.S. presence.
- 2000s: Roche solidifies its position as the world leader in in vitro diagnostics and continues to innovate in oncology, neurology, and hematology. The company launches 21 new medicines in the past decade, setting new standards of care.
- 2010s: Roche embraces digital health and AI, integrating these technologies into drug development and diagnostics to enhance precision and efficiency.
- 2024: Roche opens the Roche Innovation Center Basel, a state-of-the-art research facility costing CHF 1.2 billion. The center fosters interdisciplinary collaboration and sustainability, using recycled concrete, solar panels, and water-saving technologies. The company achieves a 7% sales growth, launches transformative medicines like Itovebi, and sets ambitious sustainability goals, including net-zero emissions by 2045.
Roche’s history reflects its commitment to addressing complex healthcare challenges through innovation, strategic acquisitions, and a patient-centric approach. Its evolution from a small pharmaceutical firm to a global leader underscores its adaptability and focus on long-term value creation.
Products and Services
Roche offers a diverse portfolio of pharmaceuticals and diagnostic solutions, designed to prevent, diagnose, treat, and monitor diseases. Below is a comprehensive list of key products and services, categorized by division:
Pharmaceuticals
- Vabysmo: A treatment for severe eye diseases, such as neovascular age-related macular degeneration and diabetic macular edema, improving vision outcomes.
- Phesgo: A combination therapy for HER2-positive breast cancer, administered via injection, reducing treatment time.
- Ocrevus: A monoclonal antibody for multiple sclerosis, effective in both relapsing and primary progressive forms.
- Hemlibra: A bispecific antibody for haemophilia A, reducing bleeding episodes and improving quality of life.
- Itovebi: A new breast cancer medicine launched in 2024, reducing the risk of death or disease progression by over 50%.
- PiaSky: A subcutaneous therapy for paroxysmal nocturnal haemoglobinuria (PNH), administered monthly at home, minimizing hospital visits.
- Alecensa: A targeted therapy for ALK-positive lung cancer, reducing relapse or death risk by 76% in early-stage patients.
- Gazyva/Gazyvaro: A potential treatment for lupus nephritis, showing promising phase III data for a life-threatening kidney disease.
Diagnostics
- Accu-Chek SmartGuide: A digital diabetes management solution using AI to predict blood glucose fluctuations, empowering patients like Hanna to manage their condition proactively.
- Immunodiagnostic Tests: A broad range of tests for detecting biomarkers, critical for early diagnosis and disease monitoring.
- Mass Spectrometry Solution: A fully automated platform launched in 2024, enhancing diagnostic accuracy for complex conditions.
- Diagnostic Platforms: Five new platforms introduced in 2024, supporting high-throughput testing and precision diagnostics.
- Digital Solutions: Seven digital tools launched in 2024, including AI-driven analytics for personalized healthcare.
Roche’s products and services are designed to meet patients where they are—whether in hospitals, clinics, or at home—enhancing access and improving outcomes. The company’s focus on AI and data-driven solutions ensures its offerings remain cutting-edge, addressing unmet medical needs.
Brands
Roche’s brands are synonymous with innovation and quality in healthcare. Below is a comprehensive list of key brands, primarily associated with its pharmaceutical and diagnostic products:
- Vabysmo: A leading brand for severe eye disease treatments, known for its efficacy in preserving vision.
- Phesgo: A trusted brand for breast cancer therapy, offering a convenient administration method.
- Ocrevus: A globally recognized brand for multiple sclerosis, widely adopted in neurology.
- Hemlibra: A breakthrough brand for haemophilia A, transforming patient care.
- Itovebi: A new brand introduced in 2024, gaining traction for breast cancer treatment.
- PiaSky: A novel brand for PNH, enabling at-home treatment.
- Alecensa: A prominent brand for lung cancer, known for its significant impact on survival rates.
- Gazyva/Gazyvaro: A dual-branded therapy (depending on the region) for lymphoma and potential lupus nephritis treatment.
- Accu-Chek: A flagship diagnostics brand, particularly for diabetes management, with the Accu-Chek SmartGuide as a standout product.
- Cobas: A leading brand for diagnostic platforms, used in laboratories worldwide for high-throughput testing.
These brands reflect Roche’s commitment to delivering first-in-class and best-in-class solutions, with each brand tailored to specific therapeutic or diagnostic needs. All trademarks are legally protected, ensuring brand integrity and market trust.
Geographical Presence
Roche’s global footprint spans numerous countries, with a presence in leading science clusters to attract talent and deliver solutions efficiently. The company operates research and development centers, manufacturing facilities, and commercial operations worldwide, ensuring access to its medicines and diagnostics in both developed and emerging markets. Key initiatives, such as pre-eclampsia screening in Latin America and the EMPOWER 2.0 program in Kenya (screening over 300,000 women for cervical and breast cancer), highlight Roche’s commitment to reaching remote and economically disadvantaged regions.
While the document does not provide a detailed revenue breakup by geography, Roche’s global operations are implied to be balanced across major markets, with significant contributions from North America, Europe, and emerging regions. The following table estimates the revenue distribution based on the company’s global reach and market emphasis:
| Region | Estimated Revenue Contribution (%) | Key Activities |
|---|---|---|
| North America | ~40% | Strong presence via Genentech, major market for oncology and neurology products. |
| Europe | ~35% | Headquarters in Basel, new Roche Innovation Center, extensive R&D and manufacturing. |
| Asia-Pacific | ~15% | Growing market for diagnostics and oncology, partnerships for local access. |
| Latin America, Africa, Others | ~10% | Initiatives like EMPOWER 2.0 and pre-eclampsia screening to enhance access. |
Note: Revenue percentages are estimated based on Roche’s global operations and emphasis on key markets like North America and Europe, with growing contributions from emerging regions.
Financial Performance
Roche’s financial performance in 2024 reflects its strong growth and operational efficiency. The company reported Group sales of CHF 60.5 billion, a 7% increase at constant exchange rates, with the base business (excluding COVID-19) growing by 9%. Core operating profit rose by 14%, and core earnings per share (EPS) increased by 7% (12% excluding the 2023 tax dispute resolution effect). IFRS net income reached CHF 9.2 billion, supporting a proposed dividend of CHF 9.70 per share, marking the 38th consecutive increase.
Below are the consolidated financial statements for 2024, presented in tables as derived from the document:
Consolidated Profit & Loss Statement (2024)
| Item | Amount (CHF Billion) |
|---|---|
| Group Sales | 60.5 |
| Core Operating Profit | Not specified (14% growth) |
| IFRS Net Income | 9.2 |
| Core Earnings Per Share (EPS) | Not specified (7% growth, 12% excluding tax effect) |
Note: Exact figures for core operating profit and EPS are not provided in the document but are noted for their growth rates.
Consolidated Balance Sheet (2024)
The document does not provide a detailed balance sheet, but key financial metrics include the CHF 1.2 billion investment in the Roche Innovation Center Basel and strong cash flows supporting dividend payments and R&D investments.
| Item | Amount (CHF Billion) |
|---|---|
| Total Assets | Not specified |
| Total Liabilities | Not specified |
| Equity | Not specified |
| Investment in Roche Innovation Center Basel | 1.2 |
Consolidated Cash Flow Statement (2024)
The document does not provide a detailed cash flow statement, but cash flows supported significant investments, dividend payments, and operational growth.
| Item | Amount (CHF Billion) |
|---|---|
| Net Cash from Operating Activities | Not specified |
| Net Cash from Investing Activities | Not specified (includes CHF 1.2 billion for Roche Innovation Center) |
| Net Cash from Financing Activities | Not specified (includes dividend payments) |
Note: Detailed financial statements are referenced in the Finance Report, but specific figures for balance sheet and cash flow items are not detailed in the provided document.
Subsidiaries, Wholly-Owned Subsidiaries, and Associates
Roche operates through a network of subsidiaries, with Genentech being a prominent wholly-owned subsidiary. The document mentions Chugai Pharmaceutical Co., Ltd as an associate, with a former Roche director serving on its board. Below is a list based on the available information:
- Genentech (Wholly-Owned Subsidiary, 100%): A U.S.-based biotechnology company acquired in 1990, focusing on innovative medicines in oncology, immunology, and neuroscience. Genentech’s research and early development (gRED) is led by Dr. Aviv Regev.
- Chugai Pharmaceutical Co., Ltd (Associate, Percentage Not Specified): A Japan-based pharmaceutical company with Roche representation on its board. Dr. Christoph Franz, a former Roche director, received remuneration for his role in 2024.
While the document does not provide a full list of subsidiaries, Roche’s global operations imply additional subsidiaries in various regions, particularly for manufacturing and commercial activities. The Finance Report (Note 32) contains further details on related parties, but specific ownership percentages for other subsidiaries are not disclosed.
Physical Properties
Roche’s physical infrastructure supports its global R&D, manufacturing, and commercial operations. Key properties mentioned include:
- Roche Innovation Center Basel (Basel, Switzerland): Opened in 2024 with a CHF 1.2 billion investment, this state-of-the-art R&D facility features advanced labs, interdisciplinary collaboration spaces, and sustainable design (recycled concrete, rooftop solar panels, water-saving systems). It fosters innovation in biology, chemistry, and IT.
- Headquarters (Basel, Switzerland): The corporate headquarters at 4070 Basel serves as the global hub for strategy, governance, and operations.
- Global R&D Centers: Autonomous research centers worldwide, including Genentech’s facilities in the U.S., support diverse scientific approaches.
- Manufacturing Facilities: Roche operates production sites globally, though specific locations are not detailed in the document. These facilities support the supply of medicines and diagnostics.
The Roche Innovation Center Basel exemplifies the company’s commitment to sustainability, with energy-efficient designs and biodiversity-focused initiatives.
Founders
Roche was founded by Fritz Hoffmann-La Roche in 1896 in Basel, Switzerland. A visionary entrepreneur, Fritz Hoffmann recognized the potential of standardized medicines in an era when pharmaceuticals were often inconsistent. His commitment to quality and innovation laid the foundation for Roche’s growth into a global leader. The Hoffmann family remains influential, with André Hoffmann and Dr. Jörg Duschmalé, descendants of the founder, serving on the Board of Directors and representing a shareholder group with pooled voting rights holding 64.97% of issued shares as of 2024.
Board of Directors
Roche’s Board of Directors as of December 31, 2024, comprises experienced leaders overseeing strategy, governance, and sustainability. Below is a detailed list of directors:
- Dr. Severin Schwan (Born 1967, Chairman): Leads the board, focusing on innovation and sustainability. Previously CEO, he holds long-term incentives from his prior role.
- André Hoffmann (Born 1958, Vice-Chairman): Represents the shareholder group with pooled voting rights, emphasizing long-term value creation.
- Dr. Jörg Duschmalé (Born 1984): Represents the shareholder group, contributing to governance and strategy.
- Dr. Patrick Frost (Born 1968): Brings financial expertise to the board, serving on multiple committees.
- Anita Hauser (Born 1969): Contributes to governance and sustainability oversight.
- Prof. Dr. Richard P. Lifton (Born 1953): A scientific advisor, serving on the Genentech Scientific Resource Board, with honoraria of USD 22,000 in 2024.
- Dr. Jemilah Mahmood (Born 1959): Focuses on global health and equity, enhancing Roche’s social impact.
- Dr. Mark Schneider (Born 1965): Provides strategic and business insights.
- Dr. Claudia Suessmuth Dyckerhoff (Born 1967): Supports governance and innovation strategies.
- Prof. Dr. Akiko Iwasaki (Joined 2023): A scientific advisor, receiving USD 22,000 for Genentech Scientific Resource Board service in 2024.
Former member Bernard Poussot served until March 2024. The board’s remuneration for 2024 totaled CHF 9,073,525, with detailed breakdowns provided in the Remuneration Report.
Shareholding Details
Roche’s shareholding structure includes a significant portion controlled by a shareholder group with pooled voting rights, comprising André Hoffmann, Dr. Jörg Duschmalé, and members of the founder’s families. As of December 31, 2024, this group held 69,318,000 shares, representing 64.97% of issued shares. Additional shareholdings by board members and closely associated persons include Roche shares, non-voting equity securities (NES), and American Depositary Receipts (ADRs). Dr. Severin Schwan holds significant long-term incentives (S-SARs and RSUs) from his prior role as CEO.
Parent Company
Roche Holding Ltd, based in Basel, Switzerland, is the parent company of the Roche Group. It oversees the global operations of its subsidiaries, including Genentech, and maintains strategic control over the Pharmaceuticals and Diagnostics divisions. No higher parent company is mentioned, as Roche Holding Ltd is the ultimate holding entity.
Investment Details
Roche’s investments focus on R&D, infrastructure, and strategic acquisitions. Key investments in 2024 include:
- Roche Innovation Center Basel: A CHF 1.2 billion investment in a state-of-the-art R&D facility, enhancing innovation and sustainability.
- Four Strategic Acquisitions: Expanded the portfolio in cancer, autoimmune diseases, eye diseases, and obesity, though specific companies and investment amounts are not detailed.
- Partnerships: Collaborations with over 250 external partners to foster innovation, with no specific investment percentages provided.
No passive investment details (e.g., stakes in unrelated companies) are specified in the document.
Future Investment Plans
Roche plans to continue investing along its entire value chain to enhance patient outcomes and sustainability. Key future investment areas include:
- R&D Acceleration: Roche expects results from 12 phase III trials in 2025 and significant progress in early clinical development, requiring substantial R&D investments.
- AI and Digital Health: Continued investment in AI to enhance drug development and diagnostics, leveraging anonymized patient data for precision medicine.
- Sustainability Initiatives: Investments to achieve net-zero emissions by 2045 and absolute zero by 2050, including energy-efficient facilities and sustainable product development.
- Global Health Equity: Expanding programs like EMPOWER 2.0 and pre-eclampsia screening to improve access in underserved regions.
- Strategic Acquisitions and Partnerships: Ongoing investments in external innovations to bolster the pipeline in oncology, neurology, and cardiovascular-metabolic diseases.
These investments align with Roche’s strategy to prevent, stop, and cure diseases while reducing healthcare system costs and enhancing sustainability.
Roche’s unwavering commitment to innovation, sustainability, and patient-centric healthcare positions it as a global leader in pharmaceuticals and diagnostics. With a robust pipeline, strategic investments, and a focus on health equity, Roche is poised to shape the future of healthcare for generations to come.
